Alume Biosciences to begin nerve imaging clinical trial for spine surgery

Alan Condon -   Print  |

The FDA on May 4 granted biotechnology company Alume Biosciences permission to investigate the use of a nerve imaging drug during spine surgery, Biospace reports.

Alume's ALM-488 peptide-dye conjugate is designed for the fluorescent highlighting of nerves during head and neck procedures.

ALM-488 binds to the extracellular matrix of nerves, allowing real-time nerve illumination intraoperatively.

The phase 1/2 trial will explore the safety and efficacy of ALM-488 in up to 36 patients undergoing surgery.

Beginning in the second quarter, the trial will take place at the University California San Diego, Stanford Medical Center in Palo Alto, Calif., and Harvard-Massachusetts Eye & Ear in Boston.

More articles on biologics:
Geoff Martha, Kevin Lobo & more: 5 CEOs to know in the spine industry
Wright Medical inches toward sale, makes pay cuts due to pandemic: 5 updates
How COVID-19 has affected Medtronic, Stryker, Johnson & Johnson's shares over the last month

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers